The U.S. Food and Drug Administration has ordered manufacturers of popular GLP-1 drugs, including Ozempic and Wegovy, to add warnings to their labels regarding a rare condition that can lead to vision loss. This condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), has been identified as a potential risk associated with these widely used medications.
While the FDA acknowledges that the risk appears to be small and the data is mixed, the agency is prioritizing patient awareness. The mandate comes as GLP-1 drugs continue to gain traction for weight loss and diabetes management, with companies like Novo Nordisk and Eli Lilly seeing significant success. However, concerns have also been raised about the potential diversion of pharmaceutical focus from essential diabetes treatments like insulin to these blockbuster weight-loss medications, potentially impacting access in poorer countries.
FDA Mandates Warnings for GLP-1 Drugs Over Rare Vision Loss Risk
3 stories · 3 sources
Sources
- Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness — BBC World,
- FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss — Ars Technica,
- Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn — The Guardian World,